Want to see VRDN full AI Analyst Report?
VRDN Stock Chart & Stats
$14.80
-$0.50(-1.51%)
At close: 4:00 PM EST
$14.80
-$0.50(-1.51%)
Day’s Range― - ―
52-Week Range$13.18 - $34.29
Previous CloseN/A
Volume140.31K
Average Volume (3M)2.19M
Market Cap
$2.12B
Enterprise Value$1.42K
Total Cash (Recent Filing)$762.18M
Total Debt (Recent Filing)$51.17M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Aug 12, 2026EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.48
Shares Outstanding110,427,680
10 Day Avg. Volume1,659,274
30 Day Avg. Volume2,187,022
Financial Highlights & Ratios
PEG Ratio0.57
Price to Book (P/B)3.65
Price to Sales (P/S)37.25
P/FCF Ratio-9.53
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$33.91Price Target Upside129.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-3.81
Revenue Forecast (FY)$21.40M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Capital BaseLow leverage and a sizable equity base reduce refinancing risk and fixed interest burden, giving management flexibility to fund pivotal filing, manufacturing scale-up, and early commercialization investments. This structural balance-sheet strength supports runway over the next several quarters.
Pivotal Phase 3 SuccessTwo successful pivotal Phase 3 trials materially de-risk the core IGF-1R program and underpin planned regulatory submissions and a potential launch. Durable clinical validation strengthens regulatory positioning and commercial optionality over the medium term.
Manufacturing Supply AgreementA multi-year commercial manufacturing agreement with WuXi secures scalable drug substance and product supply while allowing alternate suppliers. This operational arrangement reduces launch bottlenecks and supports predictable supply and costs during commercialization build-out.
Bears Say
High Cash BurnSustained heavy cash burn requires ongoing external funding to maintain R&D, regulatory filings, and launch preparations. Persistent negative operating and free cash flow increases dilution risk and constrains strategic flexibility if timelines or outcomes shift.
Very Large Operating LossesDeep operating losses and sharply negative net income indicate profitability is distant and margins are structurally weak pre-commercialization. This financial profile forces reliance on external capital or partnerships to achieve sustainable margins post-launch.
No Product Revenue / Funding RelianceAs a clinical-stage biotech with no marketed products, Viridian depends on periodic financing to fund operations and development. That structural dependence raises dilution risk and could limit the company's ability to scale commercialization investments until revenue streams materialize.
Viridian Therapeutics News
VRDN FAQ
What was Viridian Therapeutics, Inc.’s price range in the past 12 months?
Viridian Therapeutics, Inc. lowest stock price was $13.18 and its highest was $34.29 in the past 12 months.
What is Viridian Therapeutics, Inc.’s market cap?
Viridian Therapeutics, Inc.’s market cap is $2.12B.
When is Viridian Therapeutics, Inc.’s upcoming earnings report date?
Viridian Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 19 days.
How were Viridian Therapeutics, Inc.’s earnings last quarter?
Viridian Therapeutics, Inc. released its earnings results on May 05, 2026. The company reported -$0.9 earnings per share for the quarter, beating the consensus estimate of -$1.081 by $0.181.
Is Viridian Therapeutics, Inc. overvalued?
According to Wall Street analysts Viridian Therapeutics, Inc.’s price is currently Undervalued.
Does Viridian Therapeutics, Inc. pay dividends?
Viridian Therapeutics, Inc. does not currently pay dividends.
What is Viridian Therapeutics, Inc.’s EPS estimate?
Viridian Therapeutics, Inc.’s EPS estimate is -1.02.
How many shares outstanding does Viridian Therapeutics, Inc. have?
Viridian Therapeutics, Inc. has 110,427,680 shares outstanding.
What happened to Viridian Therapeutics, Inc.’s price movement after its last earnings report?
Viridian Therapeutics, Inc. reported an EPS of -$0.9 in its last earnings report, beating expectations of -$1.081. Following the earnings report the stock price went up 33.357%.
Which hedge fund is a major shareholder of Viridian Therapeutics, Inc.?
Currently, no hedge funds are holding shares in VRDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viridian Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.91 (129.12% Upside)
$33.91 (129.12% Upside)
Blogger Sentiment
Bullish
VRDN Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 16.2%
Last 30 Days ▲ 16.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
13.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.37%
Trailing 12-Months
Company Description
Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
VRDN Stock 12 Month Forecast
Average Price Target
$33.91
▲(129.12% Upside)
Technical Analysis
Dianthus Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
4.66% Insiders
26.25% Mutual Funds
0.40% Other Institutional Investors
53.10% Public Companies and
Individual Investors